EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Effect of Teneligliptin 20 mg Twice Daily on Glucagon-Like Peptide-1 Levels and Its Influence on Non-Glycemic Components in Non-Diabetic Obese Individuals

Ranakishor Pelluri, Srikanth Kongara, Vanitha Rani Nagasubramanian iD, Shriraam Mahadevan, Jithendra Chimakurthy

Metabolic Syndrome and Related Disorders · 2024-03 · 22 (2) · 90-96

DOI: 10.1089/met.2023.0218 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Metabolic Syndrome and Related Disorders, online erschienen am 14.03.2024. Verfasst von Ranakishor Pelluri und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice, Sri Ramachandra Institute of Higher Education Research, (Deemed to be University), Chennai, India. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Insulin Resistance, Dipeptidyl-Peptidase IV Inhibitors, Pyrazoles. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims: Teneligliptin is an oral antidiabetic agent, it can persevere glucagon-like peptide-1 (GLP-1) by inhibiting dipeptidyl peptidase enzyme. In addition, it has rare incidence of hypoglycemia. Hence, this study aimed to test the effect of teneligliptin 20 mg twice daily along with low carbohydrate diet and physical exercise on change of body weight and insulin resistance in nondiabetic obese subjects. Materials and Methods: It is a prospective, randomized, double-blind, placebo-controlled, parallel group study carried out at outpatient department of an endocrinology hospital over the period of 48 weeks. Teneligliptin 20 mg twice daily 30 min before food (low carbohydrate diet [LCD]) with regular physical exercise, and control group was kept with placebo twice daily 30 min before food LCD with regular physical exercise. This study was registered in clinical trial registry of India [CTRI/2020/02/023329].

Results

A total of 150 nondiabetic obese subjects were randomized into test ( n = 75) and control groups ( n = 75). At the end of 48 weeks there was significant improvement in GLP-1, simplified nutrition assessment questionnaire (SNAQ) score, homeostasis model assessment of insulin resistance (HOMA-IR), triglycerides (TG), and body weight. The mean difference and 95% confidence interval of GLP-1 (pg/mL) was 76.42 (44.42–148.41) ( P = 0.37); SNAQ score, −1.64 (−2.48 to −0.81) ( P = 0.000); HOMA-IR, −0.9 (−0.59 to −0.38) ( P = 0.000); TG (mg/dL) −29.37 (−44.46 to −14.07) ( P = 0.000); reduction of body weight (kilograms) −3.09 (−6.11 to −0.07) ( P = 0.043).

Conclusion

Findings of this study reveals that teneligliptin-treated group showed significant improvement in GLP-1 levels, reduced insulin resistance, body weight, TG, appetite, and metabolic syndrome. Teneligliptin is well tolerated, except in upper respiratory tract infections. CTR number: CTRI/2020/02/023329

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Insulin ResistanceDipeptidyl-Peptidase IV InhibitorsPyrazolesThiazolidinesHumansGlucagon-Like Peptide 1Blood GlucoseProspective StudiesHypoglycemic AgentsObesityBody Weight

Stichwörter der Autor:innen

GLP-1insulin resistancenondiabeticsobesityteneligliptin

Substanzen

Glucagon-Like Peptide 13-(4-(4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl)pyrrolidin-2-ylcarbonyl)thiazolidineDipeptidyl-Peptidase IV InhibitorsBlood GlucoseHypoglycemic AgentsPyrazolesThiazolidines

Autor:innen und Institutionen

  • Department of Pharmacy Practice, Sri Ramachandra Institute of Higher Education Research, (Deemed to be University), Chennai, India.
  • Department of Endocrinology and Metabolism, Endolife Speciality Hospital, Guntur, India.
  • Department of Pharmaceutical Sciences, Vignan's Foundation for Science Technology and Research, (Deemed to be University), Guntur, India.
  • Department of Pharmacy Practice, Jaya College of Paramedical Sciences, College of Pharmacy, Chennai, India.
  • Department of Endocrinology and Metabolism, Sri Ramachandra Institute of Higher Education and Research, (Deemed to be University), Chennai, India.

ORCID-Profile: Vanitha Rani Nagasubramanian

Zitieren

APA

Pelluri, R., Kongara, S., Nagasubramanian, V. R., Mahadevan, S., & Chimakurthy, J. (2024). Effect of Teneligliptin 20 mg Twice Daily on Glucagon-Like Peptide-1 Levels and Its Influence on Non-Glycemic Components in Non-Diabetic Obese Individuals. Metabolic Syndrome and Related Disorders, 22(2), 90-96. https://doi.org/10.1089/met.2023.0218

Vancouver

Pelluri R, Kongara S, Nagasubramanian VR, Mahadevan S, Chimakurthy J. Effect of Teneligliptin 20 mg Twice Daily on Glucagon-Like Peptide-1 Levels and Its Influence on Non-Glycemic Components in Non-Diabetic Obese Individuals. Metabolic Syndrome and Related Disorders. 2024;22(2):90-96. doi:10.1089/met.2023.0218

BibTeX
@article{Pelluri2024,
  author = {Pelluri, Ranakishor and Kongara, Srikanth and Nagasubramanian, Vanitha Rani and Mahadevan, Shriraam and Chimakurthy, Jithendra},
  title = {Effect of Teneligliptin 20 mg Twice Daily on Glucagon-Like Peptide-1 Levels and Its Influence on Non-Glycemic Components in Non-Diabetic Obese Individuals},
  journal = {Metabolic Syndrome and Related Disorders},
  year = {2024},
  volume = {22},
  number = {2},
  pages = {90--96},
  doi = {10.1089/met.2023.0218}
}
Kostenlos starten →